LaunchTrends: Xofigo (Prostate Cancer) (US) (Wave 3) | 2014
LaunchTrends®: Xofigo is a series of three post-launch syndicated reports designed to track physician perception, uptake, and the competitive environment of newly launched Xofigo (Algeta/Bayer HealthCare’s radium-223).
LaunchTrends®: Xofigo measures the impact of this new agent on the metastatic castrate-resistant prostate cancer (mCRPC) market following launch, based on a blend of quantitative and qualitative primary research with U.S. medical oncologists. These reports evaluate physicians’ current awareness and perception of Xofigo relative to other currently available therapies for mCRPC, current and anticipated use of Xofigo, and promotional activity of Xofigo.
Related Market Assessment Reports
Report
Chronic Kidney Disease – Geographic Focus: China – Chronic Kidney Disease – China In-Depth (China)
Chronic kidney disease (CKD) is an irreversible condition requiring lifelong management. In China, CKD is notably widespread, particularly among older adults and those with chronic risk factors…
Report
Eosinophilic Esophagitis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Eosinophilic Esophagitis (US)
Eosinophilic esophagitis (EoE) is a chronic allergic inflammatory condition of the esophagus, marked by an accumulation of eosinophils. This can lead to difficulty swallowing and potentially…
Report
Metabolic Dysfunction-Associated Steatohepatitis – Unmet Need – Unmet Need – Metabolic Dysfunction-Associated Steatohepatitis (US/EU)
Metabolic dysfunction-associated steatohepatitis (MASH), previously known as nonalcoholic steatohepatitis (NASH), has the potential to be a large and lucrative therapy market owing to the disease…
